We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVAC
151
DELISTED
CureVac
CVAC
$1.38M 0.02%
17,000
-33,500
-66% -$2.56M
RCUS icon
152
Arcus Biosciences
RCUS
$3.57B
$1.32M 0.02%
+51,000
New +$1.23M
QURE icon
153
uniQure
QURE
$2.68B
$1.25M 0.01%
34,500
– –
BHVN
154
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.07M 0.01%
12,500
-12,000
-49% -$1.02M
KOS icon
155
Kosmos Energy
KOS
$1.56B
$999K 0.01%
425,000
– –
LKFT
156
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$940K 0.01%
+9,500
New +$1.16M
SQM icon
157
Sociedad Química y Minera de Chile
SQM
$19.6B
$893K 0.01%
18,200
– –
DGX icon
158
Quest Diagnostics
DGX
$25.1B
$804K 0.01%
6,749
-53,256
-89% -$6.49M
CYBR
159
DELISTED
CyberArk
CYBR
$695K 0.01%
4,300
– –
STNE icon
160
StoneCo
STNE
$2.62B
$629K 0.01%
7,500
-3,200
-30% -$214K
ALV icon
161
Autoliv
ALV
$8.6B
$626K 0.01%
6,800
– –
ADI icon
162
Analog Devices
ADI
$181B
$606K 0.01%
4,100
– –
RDY icon
163
Dr. Reddy's Laboratories
RDY
$9.82B
$606K 0.01%
42,500
– –
EL icon
164
Estee Lauder
EL
$29B
$598K 0.01%
2,248
– –
XLNX
165
DELISTED
Xilinx Inc
XLNX
$595K 0.01%
4,200
– –
MTCH icon
166
Match Group
MTCH
$8.84B
$586K 0.01%
3,878
-1,600
-29% -$212K
ULTA icon
167
Ulta Beauty
ULTA
$20.4B
$574K 0.01%
2,000
– –
IBKR icon
168
Interactive Brokers
IBKR
$40.9B
$573K 0.01%
37,600
– –
MELI icon
169
Mercado Libre
MELI
$91.3B
$570K 0.01%
340
-160
-32% -$226K
OPT
170
DELISTED
Opthea Limited American Depositary Shares
OPT
$568K 0.01%
+50,000
New +$631K
TRMB icon
171
Trimble
TRMB
$12.3B
$554K 0.01%
8,300
-3,400
-29% -$195K
ICE icon
172
Intercontinental Exchange
ICE
$82.4B
$553K 0.01%
4,800
– –
AVNT icon
173
Avient
AVNT
$3.45B
$548K 0.01%
13,600
– –
IT icon
174
Gartner
IT
$9.41B
$545K 0.01%
3,400
– –
MSCI icon
175
MSCI
MSCI
$40B
$530K 0.01%
1,186
– –
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.